Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MWA and Adoptive Immunotherapy for Hepatocellular Carcinoma
NCT02851784Phase 3Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Dec 2009
- Primary completion
- Dec 2028
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in hepatocellular carcinoma (HCC) (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoint: Overall Survival at 8 years. Started Dec 2009; status: recruiting.
02
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02851784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02851784.